MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...
MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...
an undergraduate student at Northwestern University? a high school student thinking about where to go to college? interested and strong in mathematics and data analysis? thinking about a career — or a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback